Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: This company needs strong institutional investor ownership to really climb

Without them as an anchor, the ship will drift back and forth in any direction afforded by the slightest breeze.

One thing that might (should) attract institutional investors is a dividend, unless or until some of the languishing investments take off.

At current prices a one cent dividend quarterly would be a 50% return which would be outstanding. Even 2 cents annually would be great. If the price goes up, the return would be lower but offset by a possibly significantly greater capital gain.

If this does clear the hurdles presently out there near term, there is no reason for it not to find some new investors with interest

However, a successful product company is really what is required for the long haul. Or the company must start inventing something new on its own.

It may be that someone from the BoD has presented at investor gatherings but I don't know. Maybe some of the long timers do.

Just some thoughts (which many, if not all, here have likely already considered privately)

Share
New Message
Please login to post a reply